By , (Reuters) - COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world U.S. study released on Monday.The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 U.S. healthcare personnel and first responders found.The results validate earlier studies that had indicated the vaccines begin to work soon after a first dose, and confirm that they also prevent asymptomatic infections.Some countries dealing with limited vaccine...…By , (Reuters) - COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world U.S. study released on Monday.The risk of infection fell 90% by two weeks after the second shot, the study of nearly 4,000 U.S. healthcare personnel and first responders found.The results validate earlier studies that had indicated the vaccines begin to work soon after a first dose, and confirm that they also prevent asymptomatic infections.Some countries dealing with limited vaccine...WW…

By , (Reuters) - The U.S. government will pay Pfizer Inc nearly $2 billion for 100 million additional doses of its COVID-19 vaccine to bolster its supply as the country grapples with a nationwide spike in infections.Under the new agreement, Pfizer will deliver at least 70 million doses by June 30 and the rest no later than July 31, the company said on Wednesday, bringing the total number of doses to 200 million for a total price of about $4 billion.The purchase price amounts to $19.50 per shot and is slightly higher than the $18.90 per dose that Reuters has reported the European Union has...…By , (Reuters) - The U.S. government will pay Pfizer Inc nearly $2 billion for 100 million additional doses of its COVID-19 vaccine to bolster its supply as the country grapples with a nationwide spike in infections.Under the new agreement, Pfizer will deliver at least 70 million doses by June 30 and the rest no later than July 31, the company said on Wednesday, bringing the total number of doses to 200 million for a total price of about $4 billion.The purchase price amounts to $19.50 per shot and is slightly higher than the $18.90 per dose that Reuters has reported the European Union has...WW…

By Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company’s website on Friday afternoon.The FDA said on Friday it would hold a meeting of the advisory committee on Dec. 10 at which members would discuss the vaccine. The agency declined to predict how long its review would take, although both Pfizer and U.S. Health Secretary Alex Azar have said the FDA could authorize the vaccine in mid-December.Pfizer’s shares closed up 1.4% and BioNTech shares ended 9.6% higher in New York, as the possibility of a vaccine soon raised hopes for...…By Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company’s website on Friday afternoon.The FDA said on Friday it would hold a meeting of the advisory committee on Dec. 10 at which members would discuss the vaccine. The agency declined to predict how long its review would take, although both Pfizer and U.S. Health Secretary Alex Azar have said the FDA could authorize the vaccine in mid-December.Pfizer’s shares closed up 1.4% and BioNTech shares ended 9.6% higher in New York, as the possibility of a vaccine soon raised hopes for...WW…

By , , (Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.Slideshow The news signaled progress against the novel coronavirus that has infected more than 41 million globally, including 8 million Americans and comes 10 days before a U.S. presidential election that may hinge on plans to fight the pandemic.AstraZeneca, one of the leading vaccine developers, paused its U.S. trial on Sept. 6 after a report of a serious...…By , , (Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.Slideshow The news signaled progress against the novel coronavirus that has infected more than 41 million globally, including 8 million Americans and comes 10 days before a U.S. presidential election that may hinge on plans to fight the pandemic.AstraZeneca, one of the leading vaccine developers, paused its U.S. trial on Sept. 6 after a report of a serious...WW…

By (Reuters) - Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than would be expected based on historical trends, with at least two-thirds due to COVID-19, a government report released on Tuesday showed, adding that COVID deaths likely were undercounted.The report from the U.S. Centers for Disease Control and Prevention (CDC) estimated that 299,028 more people died between Jan. 26 and Oct. 3 than the average numbers from past years would have indicated.CDC said that about 216,000 U.S. deaths from the coronavirus had been reported by the...…By (Reuters) - Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than would be expected based on historical trends, with at least two-thirds due to COVID-19, a government report released on Tuesday showed, adding that COVID deaths likely were undercounted.The report from the U.S. Centers for Disease Control and Prevention (CDC) estimated that 299,028 more people died between Jan. 26 and Oct. 3 than the average numbers from past years would have indicated.CDC said that about 216,000 U.S. deaths from the coronavirus had been reported by the...WW…

By However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3...…By However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.Based on the current results, J&J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3...WW…